Index Entries

Dario Akaberi, Janina Krambrich, Jiaxin Ling, Chen Luni, Göran Hedenstierna, Josef D. Järhult, Johan Lennerstrand, and Åke Lundkvist
September 21, 2020
Redox Biology
Uppsala University (Sweden)

Conclusions: In this study, we demonstrated that NO can inhibit the replication of SARS-CoV-2 in Vero E6 and we identified the SARS-CoV-2 main protease as a target for NO. There is a great need for effective antivirals against SARS-CoV-2 to be used in the on-going COVID-19 pandemic. Based on this study and previous studies on SARS-CoV in vitro, and in a small clinical trial, we conclude that NO may be applied for clinical use in the treatment of COVID-19 and other human coronavirus infections.”

document
COVID-19,medical treatments